FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024593231> ?p ?o ?g. }

• W2024593231 endingPage "498" @default.
• W2024593231 startingPage "491" @default.
• W2024593231 abstract "Background & AimsInconsistencies in results and guideline recommendations regarding the durability of nucleos(t)ide analogue-induced hepatitis B e antigen (HBeAg) seroconversion require clarification. We studied the long-term durability of nucleos(t)ide analogue-induced HBeAg seroconversion in patients with chronic hepatitis B virus (HBV) infection.MethodsWe performed a single-center cohort study of 132 HBeAg-positive patients who had received nucleos(t)ide analogue therapy.ResultsDuring a median treatment duration of 26 months (range, 16–43 mo), HBeAg seroconversion occurred in 46 of 132 subjects (35%). Forty-two subjects (91%) had follow-up evaluation after HBeAg seroconversion. During a median follow-up period of 59 months (range, 28–103 mo) after HBeAg seroconversion, 13 of 42 patients (31%) showed a durable remission (defined as HBeAg negative and HBV-DNA level <10,000 copies/mL). Overall, 33 of 42 subjects (79%) continued therapy after HBeAg seroconversion; of these, 22 (67%) showed serologic and/or virologic recurrence. Nine of 42 subjects (21%) discontinued therapy after HBeAg seroconversion and at least 6 months of consolidation therapy. Only 2 patients showed a durable response in the absence of therapy. Disease recurrence in patients who continued therapy after HBeAg seroconversion was preceded by the development of resistance (80% of these patients); resistance only occurred in subjects given lamivudine monotherapy. In contrast, recurrence after treatment discontinuation or noncompliance was observed in all patients given nucleos(t)ide analogues.ConclusionsInduction of HBeAg seroconversion by nucleos(t)ide analogues is temporary in most patients with chronic HBV infection. Long-term continuation of nucleos(t)ide analogue treatment, irrespective of the occurrence of HBeAg seroconversion, appears to be necessary. Inconsistencies in results and guideline recommendations regarding the durability of nucleos(t)ide analogue-induced hepatitis B e antigen (HBeAg) seroconversion require clarification. We studied the long-term durability of nucleos(t)ide analogue-induced HBeAg seroconversion in patients with chronic hepatitis B virus (HBV) infection. We performed a single-center cohort study of 132 HBeAg-positive patients who had received nucleos(t)ide analogue therapy. During a median treatment duration of 26 months (range, 16–43 mo), HBeAg seroconversion occurred in 46 of 132 subjects (35%). Forty-two subjects (91%) had follow-up evaluation after HBeAg seroconversion. During a median follow-up period of 59 months (range, 28–103 mo) after HBeAg seroconversion, 13 of 42 patients (31%) showed a durable remission (defined as HBeAg negative and HBV-DNA level <10,000 copies/mL). Overall, 33 of 42 subjects (79%) continued therapy after HBeAg seroconversion; of these, 22 (67%) showed serologic and/or virologic recurrence. Nine of 42 subjects (21%) discontinued therapy after HBeAg seroconversion and at least 6 months of consolidation therapy. Only 2 patients showed a durable response in the absence of therapy. Disease recurrence in patients who continued therapy after HBeAg seroconversion was preceded by the development of resistance (80% of these patients); resistance only occurred in subjects given lamivudine monotherapy. In contrast, recurrence after treatment discontinuation or noncompliance was observed in all patients given nucleos(t)ide analogues. Induction of HBeAg seroconversion by nucleos(t)ide analogues is temporary in most patients with chronic HBV infection. Long-term continuation of nucleos(t)ide analogue treatment, irrespective of the occurrence of HBeAg seroconversion, appears to be necessary." @default.
• W2024593231 created "2016-06-24" @default.
• W2024593231 creator A5028863292 @default.
• W2024593231 creator A5031051209 @default.
• W2024593231 creator A5043626370 @default.
• W2024593231 creator A5057929739 @default.
• W2024593231 creator A5084833963 @default.
• W2024593231 date "2010-08-01" @default.
• W2024593231 modified "2023-10-14" @default.
• W2024593231 title "Nucleos(t)ide Analogues Only Induce Temporary Hepatitis B e Antigen Seroconversion in Most Patients With Chronic Hepatitis B" @default.
• W2024593231 cites W1581971337 @default.
• W2024593231 cites W1963875503 @default.
• W2024593231 cites W1969872269 @default.
• W2024593231 cites W1974899949 @default.
• W2024593231 cites W1982812988 @default.
• W2024593231 cites W1996220203 @default.
• W2024593231 cites W2004100607 @default.
• W2024593231 cites W2007456624 @default.
• W2024593231 cites W2015804238 @default.
• W2024593231 cites W2032812836 @default.
• W2024593231 cites W2039229349 @default.
• W2024593231 cites W2040562731 @default.
• W2024593231 cites W2040989067 @default.
• W2024593231 cites W2049245776 @default.
• W2024593231 cites W2053396830 @default.
• W2024593231 cites W2063885826 @default.
• W2024593231 cites W2081019716 @default.
• W2024593231 cites W2083948285 @default.
• W2024593231 cites W2084713036 @default.
• W2024593231 cites W2088577648 @default.
• W2024593231 cites W2089136108 @default.
• W2024593231 cites W2092848928 @default.
• W2024593231 cites W2094281766 @default.
• W2024593231 cites W2104389844 @default.
• W2024593231 cites W2110696711 @default.
• W2024593231 cites W2122705826 @default.
• W2024593231 cites W2129456084 @default.
• W2024593231 cites W2138529156 @default.
• W2024593231 cites W2144263253 @default.
• W2024593231 cites W2156015715 @default.
• W2024593231 cites W2162559479 @default.
• W2024593231 cites W3030265267 @default.
• W2024593231 doi "https://doi.org/10.1053/j.gastro.2010.03.059" @default.
• W2024593231 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20381492" @default.
• W2024593231 hasPublicationYear "2010" @default.
• W2024593231 type Work @default.
• W2024593231 sameAs 2024593231 @default.
• W2024593231 citedByCount "179" @default.
• W2024593231 countsByYear W20245932312012 @default.
• W2024593231 countsByYear W20245932312013 @default.
• W2024593231 countsByYear W20245932312014 @default.
• W2024593231 countsByYear W20245932312015 @default.
• W2024593231 countsByYear W20245932312016 @default.
• W2024593231 countsByYear W20245932312017 @default.
• W2024593231 countsByYear W20245932312018 @default.
• W2024593231 countsByYear W20245932312019 @default.
• W2024593231 countsByYear W20245932312020 @default.
• W2024593231 countsByYear W20245932312021 @default.
• W2024593231 countsByYear W20245932312022 @default.
• W2024593231 crossrefType "journal-article" @default.
• W2024593231 hasAuthorship W2024593231A5028863292 @default.
• W2024593231 hasAuthorship W2024593231A5031051209 @default.
• W2024593231 hasAuthorship W2024593231A5043626370 @default.
• W2024593231 hasAuthorship W2024593231A5057929739 @default.
• W2024593231 hasAuthorship W2024593231A5084833963 @default.
• W2024593231 hasBestOaLocation W20245932311 @default.
• W2024593231 hasConcept C126322002 @default.
• W2024593231 hasConcept C159047783 @default.
• W2024593231 hasConcept C159654299 @default.
• W2024593231 hasConcept C203014093 @default.
• W2024593231 hasConcept C2522874641 @default.
• W2024593231 hasConcept C2775940106 @default.
• W2024593231 hasConcept C2777382497 @default.
• W2024593231 hasConcept C2777410769 @default.
• W2024593231 hasConcept C2777451964 @default.
• W2024593231 hasConcept C2777869810 @default.
• W2024593231 hasConcept C2778715236 @default.
• W2024593231 hasConcept C2780593183 @default.
• W2024593231 hasConcept C3020491458 @default.
• W2024593231 hasConcept C45189115 @default.
• W2024593231 hasConcept C71924100 @default.
• W2024593231 hasConcept C90924648 @default.
• W2024593231 hasConceptScore W2024593231C126322002 @default.
• W2024593231 hasConceptScore W2024593231C159047783 @default.
• W2024593231 hasConceptScore W2024593231C159654299 @default.
• W2024593231 hasConceptScore W2024593231C203014093 @default.
• W2024593231 hasConceptScore W2024593231C2522874641 @default.
• W2024593231 hasConceptScore W2024593231C2775940106 @default.
• W2024593231 hasConceptScore W2024593231C2777382497 @default.
• W2024593231 hasConceptScore W2024593231C2777410769 @default.
• W2024593231 hasConceptScore W2024593231C2777451964 @default.
• W2024593231 hasConceptScore W2024593231C2777869810 @default.
• W2024593231 hasConceptScore W2024593231C2778715236 @default.
• W2024593231 hasConceptScore W2024593231C2780593183 @default.
• W2024593231 hasConceptScore W2024593231C3020491458 @default.
• W2024593231 hasConceptScore W2024593231C45189115 @default.
• W2024593231 hasConceptScore W2024593231C71924100 @default.
• W2024593231 hasConceptScore W2024593231C90924648 @default.

• next